CJC-1295 + Ipamorelin (5mg/5mg)

$80.00

CJC-1295 (no DAC) combined with Ipamorelin at a balanced 5mg/5mg ratio is one of the most studied growth-hormone–releasing peptide stacks used in research to examine natural GH pulsatility, metabolic function, cellular repair, recovery pathways, and age-related decline. This synergistic pairing is designed to amplify growth-hormone secretion through both GHRH- and GHRP-based pathways, offering a dual-mechanism model for researchers studying regeneration, fat metabolism, tissue repair, and peptide-based endocrine modulation.

95 in stock

Research Benefits

What Is CJC-1295 + Ipamorelin?

This combination pairs two of the most respected GH secretagogues in research: CJC-1295 (no DAC), a GHRH analog that stimulates GH from the pituitary, and Ipamorelin, a selective ghrelin receptor agonist known for its clean, cortisol-neutral profile. Together, they create a dual-action model that amplifies natural GH pulses while supporting IGF-1 activation, cellular repair pathways, and metabolic improvement.

Why Choose CJC-1295 + Ipamorelin for Research?

The synergy between CJC-1295 (no DAC) and Ipamorelin is considered one of the most predictable and physiologically relevant ways to study GH enhancement. Instead of forcing unnaturally high GH levels (as seen with DAC), this version allows researchers to model natural pulsation, receptor sensitivity preservation, and circadian GH activity. This makes it ideal for studies involving aging, tissue repair, fat metabolism, mitochondrial regeneration, and hormonal optimization.

FAQS

It is a dual-pathway GH secretagogue combination where CJC-1295 (no DAC) stimulates the GHRH receptor while Ipamorelin activates the ghrelin receptor, producing synergistic GH release.

No DAC is preferred in many studies because it produces pulsatile GH secretion — more physiological and useful for anti-aging, metabolic, and recovery-based research.

Improved GH pulsatility, enhanced IGF-1 activity, increased recovery, fat-loss pathway activation, and regenerative biology support.

Yes. Many researchers combine CJC/Ipa with Tesamorelin for deeper visceral fat and metabolic studies.

Yes. This is a trending triple-agonist stack in GH research for layered amplitude (CJC-1295), frequency (Ipamorelin), and baseline enhancement (Sermorelin).

It refers to a 5mg CJC-1295 (no DAC) and 5mg Ipamorelin pairing — standardized for synergistic GH stimulation models.

CJC increases GH pulse amplitude; Ipamorelin increases pulse frequency. Together they create a strong but physiologic GH profile.

Yes. It does not significantly raise cortisol, prolactin, or desensitize receptors like GHRP-2 and GHRP-6.

Does this stack support fat-metabolism research?

Yes, GH naturally spikes at night, and this combination is widely studied in sleep-recovery models.

Related Products